Related Experiment Video
Updated: Aug 8, 2026
07:08
A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
[Clusterin as a biomarker for Alzheimer's disease]
O V Alpidovskaya1, B V Tikhonov1
1Chuvash state university named after I.N. Ulyanov, Cheboksary, Russia.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova
|August 7, 2026
Summary
Clusterin (CLU) shows significant potential as an Alzheimer's disease biomarker. Measuring plasma CLU levels may aid in early screening and therapeutic strategies for AD.
Area of Science:
- Neuroscience
- Biochemistry
- Genetics
Background:
- Alzheimer's disease (AD) poses a significant global health challenge.
- Identifying reliable biomarkers for early AD detection is crucial for timely intervention.
- Clusterin (CLU) has emerged as a protein of interest in AD research.
Purpose of the Study:
- To systematically review the literature on clusterin (CLU) as a potential biomarker for Alzheimer's disease (AD).
- To elucidate the role of CLU in AD pathogenesis and its implications for early detection.
Main Methods:
- Comprehensive literature search of PubMed and other scientific databases over the past decade.
- Systematic analysis and synthesis of findings from Russian and international publications.
- Analytical scrutiny of collected data to determine CLU's significance in AD.
Main Results:
- Clusterin (CLU) is implicated in AD pathogenesis through inflammation regulation, apoptosis modulation, and clearance of pathological proteins.
- CLU protects cells from oxidative stress and activates the PI3K/Akt pathway, potentially influencing AD progression.
- Elevated plasma CLU levels in healthy individuals may precede amyloid-beta deposition by up to ten years, suggesting early involvement in AD.
Conclusions:
- Clusterin (CLU) is a significant biomarker for Alzheimer's disease.
- Enzyme-linked immunosorbent assays for plasma CLU can support early AD screening.
- Measuring CLU may offer a valuable tool for early AD detection and therapeutic interventions.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...